Microsoft-backed (MSFT) AI firm OpenAI (PC:OPAIQ) is considering expanding into healthcare, according to Business Insider. More precisely, the company is exploring new consumer health tools, such as a personal health assistant or a platform that gathers and organizes medical data. This could allow OpenAI to succeed in a space where other tech giants like Google (GOOGL), Amazon (AMZN), and Microsoft have struggled for years. In fact, ChatGPT has around 800 million weekly users, and many are already asking health-related questions.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Interestingly, recent hires show just how serious OpenAI is about healthcare. In June, it brought in Nate Gross, cofounder of Doximity (DOCS), to lead its healthcare strategy. It also hired Ashley Alexander from Instagram as its Vice President of Health Products. Experts say that OpenAI might finally solve the long-standing “personal health record” problem, where medical data is scattered across different doctors and systems. It’s worth noting that previous attempts by Apple (AAPL), Google, and Microsoft failed mainly because users had to manually upload data, or hospitals were slow to share records.
However, a recent U.S. rule banning “information blocking” is starting to change that, and companies like Health Gorilla and Particle Health now act as intermediaries that can help aggregate medical data for AI systems like OpenAI’s. Nevertheless, for now, OpenAI isn’t asking users to share personal medical records and is sticking to general health information in ChatGPT. In addition, company leaders say that they plan to collaborate with healthcare partners rather than store or manage sensitive data themselves.
Is MSFT Stock a Good Buy?
Turning to Wall Street, analysts have a Strong Buy consensus rating on MSFT stock based on 34 Buys assigned in the last three months. Furthermore, the average MSFT price target of $633.14 per share implies 26% upside potential.
